<DOC>
	<DOC>NCT01290718</DOC>
	<brief_summary>This single arm. open-label study will assess the efficacy and safety of Herceptin (trastuzumab) in combination with Xeloda (capecitabine) in patients with metastatic or recurrent HER2-positive breast cancer, refractory to or relapsing after chemotherapy with Herceptin and taxanes. Patients will receive Xeloda 900mg/m2 twice daily orally on days 1-14 of each 3-week cycle and Herceptin 8mg/kg intravenously (iv) on day 1 of the first cycle followed by 6mg/kg iv every 3 weeks. The anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.</brief_summary>
	<brief_title>A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patients, 1865 years of age Histologically confirmed HER2positive breast cancer with measurable lesions (according to RECIST criteria) Metastatic disease after firstline therapy or recurrent disease after (neo)adjuvant therapy with Herceptin and taxanes ECOG performance status 02 CNS metastases which are not well controlled Simultaneous treatment with sorivudine History of another malignancy within the last 5 years except for cured basal cell carcinoma of the skin and cured carcinoma insitu of the uterine cervix Pregnant or lactating women</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>